Published in J Acquir Immune Defic Syndr on November 01, 2003
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS (2008) 9.10
Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One (2009) 8.58
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav (2006) 8.11
The utilization of testing and counseling for HIV: a review of the social and behavioral evidence. Am J Public Health (2007) 5.50
Understanding and addressing AIDS-related stigma: from anthropological theory to clinical practice in Haiti. Am J Public Health (2005) 4.85
Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med (2009) 4.34
Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. AIDS Behav (2006) 4.34
Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One (2008) 4.20
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav (2009) 3.39
Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda. J Int AIDS Soc (2010) 3.03
Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc (2013) 3.00
Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97
Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. J Acquir Immune Defic Syndr (2009) 2.62
Barriers to sustaining antiretroviral treatment in Kisesa, Tanzania: a follow-up study to understand attrition from the antiretroviral program. AIDS Patient Care STDS (2009) 2.56
The impact of universal access to antiretroviral therapy on HIV stigma in Botswana. Am J Public Health (2008) 2.56
HIV/AIDS, undernutrition, and food insecurity. Clin Infect Dis (2009) 2.33
Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr (2011) 2.32
Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One (2010) 2.24
Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: a qualitative study. AIDS Care (2009) 2.18
Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi. Bull World Health Organ (2007) 2.17
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health (2008) 1.96
Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One (2010) 1.84
Adherence to antiretroviral therapy: merging the clinical and social course of AIDS. PLoS Med (2005) 1.77
Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One (2010) 1.77
The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75
Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr (2008) 1.73
Factors influencing adherence to antiretroviral treatment in Nepal: a mixed-methods study. PLoS One (2012) 1.72
Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV AIDS (Auckl) (2013) 1.68
Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. PLoS Med (2005) 1.67
HIV stigma and missed medications in HIV-positive people in five African countries. AIDS Patient Care STDS (2009) 1.62
Exploring children's stigmatisation of AIDS-affected children in Zimbabwe through drawings and stories. Soc Sci Med (2010) 1.61
The social context of food insecurity among persons living with HIV/AIDS in rural Uganda. Soc Sci Med (2011) 1.55
Determinants of Adherence to Antiretroviral Therapy among HIV-Infected Patients in Africa. AIDS Res Treat (2012) 1.51
HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis (2012) 1.47
Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol (2007) 1.46
Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania. BMC Public Health (2013) 1.45
Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: a prospective study at Yaounde Central Hospital, Cameroon. AIDS Res Ther (2009) 1.44
Factors associated with adherence to Antiretroviral Therapy (ART) among adult people living with HIV and attending their clinical care, Eastern Ethiopia. BMC Int Health Hum Rights (2015) 1.40
Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS One (2012) 1.39
How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr (2006) 1.39
Contextual and psychosocial influences on antiretroviral therapy adherence in rural Zimbabwe: towards a systematic framework for programme planners. Int J Health Plann Manage (2011) 1.37
State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr (2012) 1.37
High acceptability for cell phone text messages to improve communication of laboratory results with HIV-infected patients in rural Uganda: a cross-sectional survey study. BMC Med Inform Decis Mak (2012) 1.36
Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia. AIDS Res Ther (2010) 1.35
Barriers to adherence to antiretroviral medications among patients living with HIV in southern China: a qualitative study. AIDS Care (2008) 1.34
Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review. AIDS Behav (2014) 1.31
The impact of taking or not taking ARVs on HIV stigma as reported by persons living with HIV infection in five African countries. AIDS Care (2009) 1.30
Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology (2008) 1.30
Knowledge, perception about antiretroviral therapy (ART) and prevention of mother-to-child-transmission (PMTCT) and adherence to ART among HIV positive women in the Ashanti Region, Ghana: a cross-sectional study. BMC Womens Health (2013) 1.29
Understanding the facilitators and barriers of antiretroviral adherence in Peru: a qualitative study. BMC Public Health (2010) 1.24
Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia. PLoS One (2014) 1.20
Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association "Espoir Vie Togo" in Togo, West Africa. BMC Clin Pharmacol (2010) 1.18
The consequences of post-election violence on antiretroviral HIV therapy in Kenya. AIDS Care (2011) 1.17
Shamba Maisha: a pilot study assessing impacts of a micro-irrigation intervention on the health and economic wellbeing of HIV patients. BMC Public Health (2010) 1.16
Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt) (2013) 1.14
Economic support to patients in HIV and TB grants in rounds 7 and 10 from the global fund to fight AIDS, tuberculosis and malaria. PLoS One (2014) 1.14
A review of the role of food insecurity in adherence to care and treatment among adult and pediatric populations living with HIV and AIDS. AIDS Behav (2014) 1.13
Depressive symptoms and food insufficiency among HIV-infected crack users in Atlanta and Miami. AIDS Behav (2011) 1.13
High rates of adherence and treatment success in a public and public-private HIV clinic in India: potential benefits of standardized national care delivery systems. BMC Health Serv Res (2011) 1.12
Food insufficiency among HIV-infected crack-cocaine users in Atlanta and Miami. Public Health Nutr (2010) 1.12
Rethinking HIV exceptionalism: the ethics of opt-out HIV testing in sub-Saharan Africa. Bull World Health Organ (2010) 1.12
Livelihood security and adherence to antiretroviral therapy in low and middle income settings: a systematic review. PLoS One (2011) 1.09
Are integrated HIV services less stigmatizing than stand-alone models of care? A comparative case study from Swaziland. J Int AIDS Soc (2013) 1.09
HIV care for geographically mobile populations. Mt Sinai J Med (2011) 1.07
The dynamic relationship between social support and HIV-related stigma in rural Uganda. Ann Behav Med (2014) 1.07
Evidence for the reliability and validity of the internalized AIDS-related stigma scale in rural Uganda. AIDS Behav (2013) 1.05
Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting. AIDS Care (2010) 1.05
The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?". PLoS One (2007) 1.04
Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. BMC Public Health (2010) 1.04
Food insufficiency is a risk factor for suboptimal antiretroviral therapy adherence among HIV-infected adults in urban Peru. AIDS Behav (2011) 1.02
A preliminary RCT of CBT-AD for adherence and depression among HIV-positive Latinos on the U.S.-Mexico border: the Nuevo Día study. AIDS Behav (2013) 1.01
Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav (2009) 1.01
Barriers to and facilitators of antiretroviral therapy adherence in Nepal: a qualitative study. J Health Popul Nutr (2012) 0.99
Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open (2012) 0.97
Determinants of optimal adherence over time to antiretroviral therapy amongst HIV positive adults in South Africa: a longitudinal study. AIDS Behav (2011) 0.97
Factors influencing adherence to paediatric antiretroviral therapy in Portharcourt, South- South Nigeria. Pan Afr Med J (2013) 0.95
Which patients first? Setting priorities for antiretroviral therapy where resources are limited. Am J Public Health (2005) 0.95
Socioeconomic factors in adherence to HIV therapy in low- and middle-income countries. J Health Popul Nutr (2013) 0.95
Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these? Global Health (2010) 0.93
Return to normal life after AIDS as a reason for lost to follow-up in a community-based antiretroviral treatment program. J Acquir Immune Defic Syndr (2012) 0.93
Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya. AIDS Res Ther (2011) 0.91
Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe. PLoS One (2011) 0.90
Predictors of raised viral load during antiretroviral therapy in patients with and without prior antiretroviral use: a cross-sectional study. PLoS One (2013) 0.90
A combination SMS and transportation reimbursement intervention to improve HIV care following abnormal CD4 test results in rural Uganda: a prospective observational cohort study. BMC Med (2015) 0.90
Falling through the cracks: unmet health service needs among people living with HIV in Atlanta, Georgia. J Assoc Nurses AIDS Care (2011) 0.89
'My dreams are shuttered down and it hurts lots'-a qualitative study of palliative care needs and their management by HIV outpatient services in Kenya and Uganda. BMC Palliat Care (2013) 0.88
A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa. AIDS Patient Care STDS (2015) 0.88
Prevalence and determinants of adherence to HAART amongst PLHIV in a tertiary health facility in south-south Nigeria. BMC Infect Dis (2013) 0.86
Patterns of geographic mobility predict barriers to engagement in HIV care and antiretroviral treatment adherence. AIDS Patient Care STDS (2014) 0.86
Framework for monitoring equity in access and health systems issues in antiretroviral therapy Programmes in southern Africa. Malawi Med J (2007) 0.85
Socioeconomic support reduces nonretention in a comprehensive, community-based antiretroviral therapy program in Uganda. J Acquir Immune Defic Syndr (2012) 0.84
High levels of retention in care with streamlined care and universal test and treat in East Africa. AIDS (2016) 0.84
Costing human rights and community support interventions as a part of universal access to HIV treatment and care in a Southern African setting. Curr HIV Res (2011) 0.82
Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs. BMC Med (2011) 0.82
Priorities for antiretroviral therapy research in sub-Saharan Africa: a 2002 consensus conference in Zambia. J Acquir Immune Defic Syndr (2004) 0.81
Factors Influencing Antiretroviral Adherence and Virological Outcomes in People Living with HIV in the Highlands of Papua New Guinea. PLoS One (2015) 0.81
HIV as a chronic disease considerations for service planning in resource-poor settings. Global Health (2011) 0.81
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med (2007) 6.65
A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med (2004) 5.68
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS (2008) 4.40
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr (2005) 4.19
Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS (2008) 3.71
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
Emergency department use among the homeless and marginally housed: results from a community-based study. Am J Public Health (2002) 3.21
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol (2005) 3.19
Bacterial coaggregation: an integral process in the development of multi-species biofilms. Trends Microbiol (2003) 3.17
Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis (2006) 3.03
A microchip CD4 counting method for HIV monitoring in resource-poor settings. PLoS Med (2005) 2.90
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS (2006) 2.77
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis (2012) 2.51
P4P4P: an agenda for research on pay-for-performance for patients. Health Aff (Millwood) (2009) 2.49
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS (2005) 2.48
Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis (2011) 2.42
Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol (2011) 2.41
A seronegative case of HIV-1 subtype C infection in Botswana. Clin Infect Dis (2007) 2.39
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother (2006) 2.23
A randomized trial of Mogen clamp versus Plastibell for neonatal male circumcision in Botswana. J Acquir Immune Defic Syndr (2013) 2.20
The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis (2007) 2.14
HIV-1 epidemic among female bar and hotel workers in northern Tanzania: risk factors and opportunities for prevention. J Acquir Immune Defic Syndr (2002) 1.96
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr (2007) 1.90
Mucosa-associated bacterial diversity in relation to human terminal ileum and colonic biopsy samples. Appl Environ Microbiol (2007) 1.84
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One (2012) 1.84
Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis (2005) 1.82
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS (2002) 1.74
Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr (2007) 1.71
Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis (2005) 1.70
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS (2006) 1.66
Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials. Biometrics (2010) 1.62
Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. J Infect Dis (2007) 1.60
Transmission of HIV-1 through breastfeeding among women in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr (2002) 1.60
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis (2011) 1.55
Acceptability of infant male circumcision as part of HIV prevention and male reproductive health efforts in Gaborone, Botswana, and surrounding areas. AIDS Behav (2010) 1.55
Trends and determinants of survival for over 200 000 patients on antiretroviral treatment in the Botswana National Program: 2002-2013. AIDS (2016) 1.54
Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses (2011) 1.52
Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses (2012) 1.50
Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One (2012) 1.48
Microbial characterization of biofilms in domestic drains and the establishment of stable biofilm microcosms. Appl Environ Microbiol (2003) 1.47
Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr (2009) 1.45
Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol (2011) 1.45
Molecular analysis of the subgingival microbiota in health and disease. Appl Environ Microbiol (2006) 1.45
Scaling up pediatric HIV care and treatment in Africa: clinical site characteristics associated with favorable service utilization. J Acquir Immune Defic Syndr (2013) 1.44
Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Clin Trials (2012) 1.43
Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS (2002) 1.41
Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS (2004) 1.41
Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr (2014) 1.40
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J Immunol Methods (2011) 1.40
Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr (2006) 1.38
HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS One (2010) 1.36
Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS One (2011) 1.35
Herpes simplex virus type 2 infection among bar and hotel workers in northern Tanzania: prevalence and risk factors. Sex Transm Dis (2003) 1.35
Predictors of herpes simplex virus type 2 prevalence and incidence among bar and hotel workers in Moshi, Tanzania. J Infect Dis (2007) 1.33